\"Novus ordo seclorum\": new applications af monoclonal antibodies in breast cancer
Journal Title: Współczesna Onkologia - Year 2005, Vol 9, Issue 10
Abstract
Trastuzumab (Herceptin) is a recombinant humanized monoclonal IgG1 antibody inhibiting selectively HER2 receptor in tumour cells, that has found a clinical application in breast cancer treatment. Until recently, this compound has been used exclusively in advanced breast cancer patients. During the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO) preliminary results of three large randomized studies were presented in which trastuzumab in combination with chemotherapy was administered in the adjuvant setting in operable breast cancer patients with HER2 expression or amplification. Two of these studies (NSABP-31 and NCCTG-N9831) were performed by the American cooperative groups: the National Surgical Adjuvant Breast and the Bowel Project (NSABP) and the North Central Cancer Treatment Group (NCCTG), and the third one (HERA) was a global enterprise coordinated by the Breast Intergroup (BIG) in Brussels. The presented results demonstrated a surprisingly positive impact of trastuzumab: the relative risk of disease failure was halved and additionally, in the two American studies the risk of death was significantly reduced. The treatment was well tolerated and the only serious adverse side effect was an increased risk of cardiotoxicity. At the same session, results of the first study of the third phase were presented showing a significant increase of time to progression associated with the addition of antiangiogenic monoclonal antibody – bevacizumab to standard chemotherapy of advanced breast cancer. This article presents the result of these studies and discusses their potential implications on changing standards of care in breast cancer.
Authors and Affiliations
Renata Duchnowska, Cezary Szczylik
Keywords
Related Articles
- EP ID EP139063
- DOI -
- Views 62
- Downloads 0
Pozarejestracyjne stosowanie leków w onkologii i hematologii w różnych grupach wiekowych
Rejestracja leku określa szczegółowo warunki zastosowania, tj. charakterystykę i wiek pacjentów, wskazania medyczne, dawkę, drogę podania, przeciwwskazania i ostrzeżenia związane ze stosowaniem. Podawanie leków w terapii...
Report from the 4-th International Symposium on Targeted Anticancer Therapies, Amsterdam March 16-18, 2006 (TAT 2006)
Ocena jakości życia chorych leczonych chirurgicznie z powodu raka odbytnicy w aspekcie czynników społeczno-demograficznych
Cel: Celem pracy była ocena wpływu czynników społeczno-demograficznych na odległą jakość życia pacjentów, leczonych chirurgicznie z powodu raka odbytnicy metodą resekcji przedniej niskiej lub wycięcia brzuszno-kroczowe...
Plazmidowy wektor ekspresyjny kodujący receptor sFLT-1 (psFLT-1) ogranicza angiogenezę i wzrost guzów L1
Antyangiogenna terapia genowa wykorzystuje geny kodujące białka ograniczające powstawanie nowych naczyń krwionośnych. W wypadku chorób nowotworowych stosowanie preparatów genowych antyangiogennych sprowadza się do prób...
The off-label drug use in oncology and hematology with emphasis on age groups
Drug approval refers to indications, patient characteristics, dosage, route of administration, contraindications and warnings. The term „off-label prescribing” refers to the use of a drug outside the terms of its marketi...